AR077208A1 - Derivados del acido trans-4-[[(5s)-5-[[[3,5-bis(trifluorometil) fenil] metil] (2-metil-2h-tetrazol-5-il) amino) -2,3,4,5-tetrahidro-7,9-dimetil-1h-1-benzazepin-1-il) metil)-ciclohexancarboxilico y sus formas cristalinas, composiciones farmaceuticas que los comprenden, su uso para preparar un medicam - Google Patents
Derivados del acido trans-4-[[(5s)-5-[[[3,5-bis(trifluorometil) fenil] metil] (2-metil-2h-tetrazol-5-il) amino) -2,3,4,5-tetrahidro-7,9-dimetil-1h-1-benzazepin-1-il) metil)-ciclohexancarboxilico y sus formas cristalinas, composiciones farmaceuticas que los comprenden, su uso para preparar un medicamInfo
- Publication number
- AR077208A1 AR077208A1 ARP100102219A ARP100102219A AR077208A1 AR 077208 A1 AR077208 A1 AR 077208A1 AR P100102219 A ARP100102219 A AR P100102219A AR P100102219 A ARP100102219 A AR P100102219A AR 077208 A1 AR077208 A1 AR 077208A1
- Authority
- AR
- Argentina
- Prior art keywords
- methyl
- tetrazol
- amino
- benzazepin
- bis
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Reivindicacion 1: Un compuesto derivado del ácido tetrazol-amino-benzazepin-ciclohexancarboxilico, caracterizado porque es el ácido trans-4-[[(5S)-5-[[[3,5-bis(trifluorometil)fenil]metil] (2-metil-2H-tetrazol-5-il)amino]-2,3,4,5-tetrahidro-7,9-dimetil-1H-1-benzazepin-1-il]metil]-ciclohexancarboxílico, un hidrato, o una sal farmacéuticamente aceptable del compuesto. Reivindicacion 3: Un compuesto de conformidad con la reivindicacion 1 o 2, caracterizado porque es el ácido trans4-[[(5S)-5-[[[3,5-bis(trifluorometil)fenil]metil] (2-metil-2H-tetrazol-5-il)amino]-2,3,4,5-tetrahidro-7,9-dimetil-1H-1-benzazepin-1-il]metil]-ciclohexancarboxílico.hidrato en forma cristalina, identificado por una configuracion de difraccion en polvo de rayos X obtenida de una fuente de CuKalfa (lamda=1.54056 Amstrong) la cual comprende picos a: a) 7,5, 9,2, 10,7, y 15,5 +/-0,2 en 2thita; o b) 7,5, 9,2, 10,7, 13,8, 15,0, 15,5, y 19,5 +/- 0,2 en 2thita; o c) 7,5, 9,2, 10,7, 13,8, 11,3, 15,0, 15,5, 17,7, 19,5, y 25,1 +/- 0,2 en 2thita.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22170809P | 2009-06-30 | 2009-06-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR077208A1 true AR077208A1 (es) | 2011-08-10 |
Family
ID=42352717
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100102219A AR077208A1 (es) | 2009-06-30 | 2010-06-23 | Derivados del acido trans-4-[[(5s)-5-[[[3,5-bis(trifluorometil) fenil] metil] (2-metil-2h-tetrazol-5-il) amino) -2,3,4,5-tetrahidro-7,9-dimetil-1h-1-benzazepin-1-il) metil)-ciclohexancarboxilico y sus formas cristalinas, composiciones farmaceuticas que los comprenden, su uso para preparar un medicam |
Country Status (37)
| Country | Link |
|---|---|
| US (2) | US8299060B2 (es) |
| EP (1) | EP2448933B1 (es) |
| JP (1) | JP5689875B2 (es) |
| KR (1) | KR101404893B1 (es) |
| CN (1) | CN102639528B (es) |
| AR (1) | AR077208A1 (es) |
| AU (1) | AU2010266537B2 (es) |
| BR (1) | BRPI1011931A2 (es) |
| CA (1) | CA2764425C (es) |
| CL (1) | CL2011003263A1 (es) |
| CO (1) | CO6480934A2 (es) |
| CR (1) | CR20110669A (es) |
| DK (1) | DK2448933T3 (es) |
| DO (1) | DOP2011000405A (es) |
| EA (1) | EA020600B1 (es) |
| EC (1) | ECSP11011551A (es) |
| ES (1) | ES2435293T3 (es) |
| GT (1) | GT201100321A (es) |
| HR (1) | HRP20130950T1 (es) |
| IL (1) | IL216655A (es) |
| JO (1) | JO2867B1 (es) |
| MA (1) | MA33385B1 (es) |
| ME (1) | ME01606B (es) |
| MX (1) | MX2011014024A (es) |
| MY (1) | MY157121A (es) |
| NZ (1) | NZ596820A (es) |
| PE (1) | PE20120538A1 (es) |
| PL (1) | PL2448933T3 (es) |
| PT (1) | PT2448933E (es) |
| RS (1) | RS52988B (es) |
| SG (1) | SG177413A1 (es) |
| SI (1) | SI2448933T1 (es) |
| TN (1) | TN2011000638A1 (es) |
| TW (1) | TWI450896B (es) |
| UA (1) | UA109409C2 (es) |
| WO (1) | WO2011002696A1 (es) |
| ZA (1) | ZA201108707B (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006012093A1 (en) * | 2004-06-24 | 2006-02-02 | Eli Lilly And Company | Compounds and methods for treating dyslipidemia |
| AR077208A1 (es) * | 2009-06-30 | 2011-08-10 | Lilly Co Eli | Derivados del acido trans-4-[[(5s)-5-[[[3,5-bis(trifluorometil) fenil] metil] (2-metil-2h-tetrazol-5-il) amino) -2,3,4,5-tetrahidro-7,9-dimetil-1h-1-benzazepin-1-il) metil)-ciclohexancarboxilico y sus formas cristalinas, composiciones farmaceuticas que los comprenden, su uso para preparar un medicam |
| TWI627167B (zh) | 2011-07-08 | 2018-06-21 | 諾華公司 | 用於高三酸甘油酯個體治療動脈粥狀硬化之方法 |
| WO2014012401A1 (zh) * | 2012-07-16 | 2014-01-23 | 上海恒瑞医药有限公司 | 苯并七元杂环类衍生物、其制备方法及其在医药上的应用 |
| CA2891710C (en) | 2013-01-31 | 2017-08-01 | Chong Kun Dang Pharmaceutical Corp. | Biaryl- or heterocyclic biaryl-substituted cyclohexene derivative compounds as cetp inhibitors |
| CN105017085B (zh) * | 2014-04-28 | 2018-06-29 | 中国科学院上海药物研究所 | 一类kcnq钾通道激动剂、其制备方法和用途 |
| EP3795695A1 (en) | 2014-07-30 | 2021-03-24 | F. Hoffmann-La Roche AG | Genetic markers for predicting responsiveness to therapy |
| TWI691331B (zh) | 2014-09-26 | 2020-04-21 | 日商興和股份有限公司 | 脂質異常症治療劑 |
| CN108456213B (zh) * | 2017-02-22 | 2021-01-15 | 浙江九洲药业股份有限公司 | 一种3-氟-4-羟基环己烷羧酸酯的制备方法 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS4948639B1 (es) | 1970-12-15 | 1974-12-23 | ||
| US6197786B1 (en) | 1998-09-17 | 2001-03-06 | Pfizer Inc | 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines |
| US6147089A (en) | 1998-09-17 | 2000-11-14 | Pfizer Inc. | Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines |
| GT199900147A (es) | 1998-09-17 | 1999-09-06 | 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas. | |
| CO5271716A1 (es) | 1999-11-30 | 2003-04-30 | Pfizer Prod Inc | Cristales de 4- carboxamino 1,2,3,4-tetrahidroquinolina 2- sustituida |
| HN2000000203A (es) | 1999-11-30 | 2001-06-13 | Pfizer Prod Inc | Procedimiento para la obtencion de 1,2,3,4-tetrahidroquinolinas 4-carboxiamino-2- sustituidas. |
| ES2259080T3 (es) | 2001-04-30 | 2006-09-16 | Pfizer Products Inc. | Procedimientos e intermedios para preparar inhibidores cetp. |
| NZ532494A (en) | 2002-08-30 | 2006-03-31 | Japan Tobacco Inc | Dibenzylamine compound and medicinal use thereof |
| PL376156A1 (en) | 2002-10-04 | 2005-12-27 | Millennium Pharmaceuticals, Inc. | Pgd2 receptor antagonists for the treatment of inflammatory diseases |
| WO2004078730A2 (en) | 2003-03-04 | 2004-09-16 | Takasago International Corporation | Method for producing optically active amines |
| US20040204450A1 (en) | 2003-03-28 | 2004-10-14 | Pfizer Inc | Quinoline and quinoxaline compounds |
| US7749992B2 (en) * | 2003-10-08 | 2010-07-06 | Eli Lilly And Company | Compounds and methods for treating dislipidemia |
| DE602005008416D1 (de) | 2004-03-26 | 2008-09-04 | Lilly Co Eli | Verbindungen zur behandlung von dyslipidemie |
| CN1972927A (zh) * | 2004-06-24 | 2007-05-30 | 伊莱利利公司 | 用于治疗血脂障碍的化合物和方法 |
| WO2006012093A1 (en) * | 2004-06-24 | 2006-02-02 | Eli Lilly And Company | Compounds and methods for treating dyslipidemia |
| US7700774B2 (en) | 2004-12-20 | 2010-04-20 | Dr. Reddy's Laboratories Ltd. | Heterocyclic compounds and their pharmaceutical compositions |
| AR077208A1 (es) * | 2009-06-30 | 2011-08-10 | Lilly Co Eli | Derivados del acido trans-4-[[(5s)-5-[[[3,5-bis(trifluorometil) fenil] metil] (2-metil-2h-tetrazol-5-il) amino) -2,3,4,5-tetrahidro-7,9-dimetil-1h-1-benzazepin-1-il) metil)-ciclohexancarboxilico y sus formas cristalinas, composiciones farmaceuticas que los comprenden, su uso para preparar un medicam |
-
2010
- 2010-06-23 AR ARP100102219A patent/AR077208A1/es unknown
- 2010-06-23 TW TW099120507A patent/TWI450896B/zh not_active IP Right Cessation
- 2010-06-24 JO JO2010211A patent/JO2867B1/en active
- 2010-06-28 DK DK10728558.7T patent/DK2448933T3/da active
- 2010-06-28 RS RS20130453A patent/RS52988B/en unknown
- 2010-06-28 SI SI201030386T patent/SI2448933T1/sl unknown
- 2010-06-28 US US13/318,874 patent/US8299060B2/en not_active Expired - Fee Related
- 2010-06-28 KR KR1020117031449A patent/KR101404893B1/ko not_active IP Right Cessation
- 2010-06-28 SG SG2011097128A patent/SG177413A1/en unknown
- 2010-06-28 PL PL10728558T patent/PL2448933T3/pl unknown
- 2010-06-28 MX MX2011014024A patent/MX2011014024A/es active IP Right Grant
- 2010-06-28 US US12/824,355 patent/US8329688B2/en not_active Expired - Fee Related
- 2010-06-28 EA EA201270099A patent/EA020600B1/ru not_active IP Right Cessation
- 2010-06-28 MY MYPI2011006319A patent/MY157121A/en unknown
- 2010-06-28 BR BRPI1011931A patent/BRPI1011931A2/pt not_active IP Right Cessation
- 2010-06-28 UA UAA201115555A patent/UA109409C2/ru unknown
- 2010-06-28 CA CA2764425A patent/CA2764425C/en not_active Expired - Fee Related
- 2010-06-28 MA MA34490A patent/MA33385B1/fr unknown
- 2010-06-28 NZ NZ596820A patent/NZ596820A/xx not_active IP Right Cessation
- 2010-06-28 CN CN201080029957.9A patent/CN102639528B/zh not_active Expired - Fee Related
- 2010-06-28 PT PT107285587T patent/PT2448933E/pt unknown
- 2010-06-28 ME MEP-2013-114A patent/ME01606B/me unknown
- 2010-06-28 PE PE2011002156A patent/PE20120538A1/es not_active Application Discontinuation
- 2010-06-28 ES ES10728558T patent/ES2435293T3/es active Active
- 2010-06-28 AU AU2010266537A patent/AU2010266537B2/en not_active Ceased
- 2010-06-28 WO PCT/US2010/040125 patent/WO2011002696A1/en active Application Filing
- 2010-06-28 EP EP10728558.7A patent/EP2448933B1/en active Active
- 2010-06-28 JP JP2012517814A patent/JP5689875B2/ja not_active Expired - Fee Related
-
2011
- 2011-11-25 ZA ZA2011/08707A patent/ZA201108707B/en unknown
- 2011-11-28 IL IL216655A patent/IL216655A/en not_active IP Right Cessation
- 2011-12-12 CR CR20110669A patent/CR20110669A/es not_active Application Discontinuation
- 2011-12-13 GT GT201100321A patent/GT201100321A/es unknown
- 2011-12-13 TN TNP2011000638A patent/TN2011000638A1/en unknown
- 2011-12-22 CO CO11177215A patent/CO6480934A2/es active IP Right Grant
- 2011-12-22 CL CL2011003263A patent/CL2011003263A1/es unknown
- 2011-12-23 EC EC2011011551A patent/ECSP11011551A/es unknown
- 2011-12-26 DO DO2011000405A patent/DOP2011000405A/es unknown
-
2013
- 2013-10-07 HR HRP20130950AT patent/HRP20130950T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR077208A1 (es) | Derivados del acido trans-4-[[(5s)-5-[[[3,5-bis(trifluorometil) fenil] metil] (2-metil-2h-tetrazol-5-il) amino) -2,3,4,5-tetrahidro-7,9-dimetil-1h-1-benzazepin-1-il) metil)-ciclohexancarboxilico y sus formas cristalinas, composiciones farmaceuticas que los comprenden, su uso para preparar un medicam | |
| AR073904A1 (es) | Formas cristalinas de derivados de tiazolidinona utiles como inmunomoduladores | |
| MX346318B (es) | Cristales. | |
| RU2015125591A (ru) | БЕНЗИЛСУЛЬФОНАМИДНЫЕ ПРОИЗВОДНЫЕ КАК МОДУЛЯТОРЫ RORc | |
| AR088755A1 (es) | Formas solidas de un inhibidor de disociacion transtiretina | |
| AR073298A1 (es) | Formas cristalinas del 2-tiazolil-4-quinolil-oxi amidas, composiciones farmaceuticas que las contienen y uso de las mismas en el tratamiento de la infeccion por hcv. | |
| BR112014008214A2 (pt) | composto, processo de síntese de peptídeo em fase sólida para preparar um composto, processo, composição e uso do composto | |
| HRP20170540T1 (hr) | Spojevi dimetilbenzojeve kiseline, korisni u liječenju upalnih stanja | |
| IN2014DN01992A (es) | ||
| CO6280489A2 (es) | (r)-2-(4-ciclopropansulfonil-fenil)-n-pirazin-2-il-3-(tetrahidropiran-4-il)-propionamida cristalina | |
| AR075418A1 (es) | Polimorfo cristalino de 3-{[5-(azetidin-1-ilcarbonil)pirazin-2-il]oxi}-5-{[(1s)-1-metil-2-(metiloxi)etil]oxi}-n-(5-metilpirazin-2-il)benzamida,composiciones farmaceuticas que los contienen, proceso para prepararla y uso de las mismas para el tratamiento de la diabetes tipo ii y/u obesidad. | |
| MY143557A (en) | Beta-crystalline form of perindopril arginine salt, process for its preparation, and pharmaceutical compositions containing it | |
| EA200801777A1 (ru) | α КРИСТАЛЛИЧЕСКАЯ ФОРМА АРГИНИНОВОЙ СОЛИ ПЕРИНДОПРИЛА, СПОСОБ ЕЁ ПОЛУЧЕНИЯ И ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, КОТОРЫЕ ЕЁ СОДЕРЖАТ | |
| IL230468B (en) | Crystalline form of the sodium salt of 4-tert-butyl-n-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzene sulfonamide | |
| BR112014001505A2 (pt) | formas polimórficas do sal de sódio de 4-terc-butil-n-[4-cloro-2- (1-óxi-piridina-4-carbonil)-fenil]-benzenossulfonamida | |
| MY161749A (en) | Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use | |
| CL2013000929A1 (es) | Forma cristalina c de la sal sodica del acido (4-(4-(5-(6-trifluoro metil piridin-3-il-amino) piridin-2-il-) fenil)-ciclohexil)-acetico; proceso de preparacion; composicion farmaceutica que lo comprende; y su uso para el tratamiento de un trastorno asociado con la actividad del dagt. | |
| PE20131327A1 (es) | Forma cristalina delta de la sal de arginina de perindoprilo, su procedimiento de preparacion, y las composiciones farmaceuticas que la contienen | |
| HK1164311A1 (en) | Certain crystalline hydrates, pharmaceutical compositions thereof and use thereof | |
| AR083256A1 (es) | Formas en estado solido del acido (e)-3-[2-(1-{[2-(5-bromo-pirimidin-2-il)-3-ciclopentil-1-metil-1h-indol-6-carbonil]-amino}-ciclobutil)-3-metil-3h-bencimidazol-5-il]-acrilico | |
| AR089078A1 (es) | Formas cristalinas de [(s)-1-carbamoil-2-(fenil-pirimidin-2-il-amino)-etil]-amida de acido 2-(2-metilamino-pirimidin-4-il)-1h-indol-5-carboxilico | |
| TH115567B (th) | ทราสนส์-4-[[(5s)-5-[[[3,5-บิส(ไทรฟลูออโรเมธิล)เฟนิล]เมธิล](2-เมธิล-2h-เททาโซล-5-อิล)อะมิโน]-2,3,4,5-เททราไฮโดร-7,9-ไดเมธิล-1h-1-เบนแซซีพิน-1-อิล]-ไซโคลเฮกเซนคาร์บอกซิลิค แอซิด | |
| CY1114514T1 (el) | Τrανs-4-[[(5s)-5-[[[3,5-δις(τριφθορομεθυλ)φαινυλ]μεθυλ](2-μεθυλ-2η-τετραζολ-5-υλ)αμινο]-2,3,4,5-τετραϋδρο-7,9-διμεθυλ-1η-1-βενζαζεπιν-1 -υλ]μεθυλ]-κυκλοεξανο-καρβοξυλικο οξυ | |
| CU20100014A7 (es) | Derivados de pirimidina útiles para el tratamiento de enfermedades inflamatorias o alérgicas | |
| HN2011003208A (es) | Acido trans-4-[[(5s)-[[[3,5-bis(trifluorometil)fenil]metil](2-metil-2h-tetrazol-5-il)amino]-2,3,4,5-tetrahidro-7,9-dimetil-1h-1-benzazepin-1-il]metil-ciclohexancarboxilico |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |